Journal of Bioequivalence & Bioavailability

Analytical method development for the determination of Olopatadine

3^rd World Congress Bioavailability & Bioequivalence

March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

G. Hima Bindu, I. Divya and M. Mathrusri Annapurna

Posters: J Bioequiv Availab

Abstract:

A simple precise and accurate spectrophotometric method was developed for the determination of Olopatadine in pharmaceutical formulations. Olopatadine is an anti‐histaminic, with selective H1 ‐receptor antagonist activity. Its principal effects are mediated via inhibition of H1 receptors. These drugs selectively bind to H1 receptors there by blocking the actions of endogenous Histamine. They act on the bronchi, capillaries, and other smooth muscles. Olopatadine is an inhibitor of the release of Histamine from the mast cell and a relatively selective H1 receptor antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. A double beam UV-VIS spectrophotometer (UV-1800, Shimadzu) connected to computer loaded with spectra manager software UV Probe was employed with spectral bandwidth of 1nm and wavelength accuracy of ? 0.3 nm with a pair of 10 mm matched quartz cells. Olopatadine has shown absorption maxima (λ max ) at 221 nm in 0.1 N sodium hydroxide. A graph was drawn by taking concentration of the drug on the x- axis and the corresponding absorbance values on the y- axis. Olopatadine follows Beer- Lambert?s law over the concentration range of 1.0-25 μg/ml (r 2 = 0.999). The % RSD in precision and accuracy studies was found to be less than 2.0. The proposed methods were validated as per the ICH guidelines. The developed methods can be successfully applied for the determination of Olopatadine in pharmaceutical formulations